Cambridge Cognition Holdings order intake above expectations (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss interim results for the six months ended 30th June 2021. Matthew talks us through the highlights, explains the increase in sales orders of 74% to £8.6 million, the effect of a successful spin-out and venture financing of Monument Therapeutics, what the launch of NeuroVocalix™ which is now ready for clinical trials means for the company and what we can expect from the company going forward.

Cambridge Cognition Holdings is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition.

You might also enjoy reading  Cambridge Cognition excellent order book, healthy pipeline and further opportunity (VIDEO)
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Cambridge Cognition Holdings order intake above expectations (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions